AFIB
Acutus Medical Inc
Acutus Medical Inc
$AFIB reports robust Q4 revenue growth and improved financials
Acutus Medical's Q4 and FY2022 unaudited financial results revealed increased revenue of $33.4M, up from $19.4M in the same period in 2021, due to demand for differentiated mapping and therapy platforms and geographic expansion. With a gross margin of 75%, the company aims to continue to improve it in 2023, while a net loss of $39.1M for 2022 narrowed from $107.3M in 2021. Acutus plans to sustain growth in 2023 through geographic expansion and driving adoption of the mapping and therapy platform. However, forward-looking statements are fraught with uncertainties, and investors should exercise caution when interpreting them.
14d ago
$AFIB